DSGN (Design Corp) Earnings per share for the trailing year

The share price history of Design Therapeutics (DSGN) on the GURU.Markets platform, where the current figure is -1.40, is driven by management's focus on correcting gene expression and strict adherence to ethics. Robust patent protection and unique platforms for combating severe ailments shield the business from price wars. In the future, the use of third-party manufacturing plants will allow the company to expand therapy without incurring capital expenditure costs.
DSGN (Design Therapeutics): analytical breakdowns and indicator data

Design Therapeutics specializes in developing DNA-based drugs through deep integration with biotechnological laboratories. This indicator measures the percentage change in net earnings per share over a rolling year, reflecting the pace of capital generation. For an investor, this is a key marker of R&D strategy effectiveness and the company's potential attractiveness for M&A transactions. Positive year-over-year EPS growth over the rolling period confirms the resilience of the business model.